Coronavirus

1684 bookmarks
Newest
The Irrefutable Argument Against Vaccine Safety - with Author Del Bigtree - YouTube
The Irrefutable Argument Against Vaccine Safety - with Author Del Bigtree - YouTube
The lecture will discuss the revelations of the CDC whistleblower Dr. William Thompson, who has provided 10,000 documents that back up his claim that the CDC knowingly committed scientific fraud to hide the connection between the MMR vaccine and autism. It will show how Del’s journey across America with the film has made him aware of a severe health crisis being caused by vaccines. Del Bigtree will explain the danger of vaccine mandates like the new law in California Sb27. Connect with The Real Truth About Health http://www.therealtruthabouthealth.com/ https://www.facebook.com/The-Real-Truth-About-Health-467500836655781/ https://www.instagram.com/therealtruthabouthealth/ https://twitter.com/RTAHealth Passionate believers in whole food plant based diets, no chemicals, minimal pharmaceutical drugs, no GMO's. Fighting to stop climate change and extinction.
·youtube.com·
The Irrefutable Argument Against Vaccine Safety - with Author Del Bigtree - YouTube
The Sordid History of Vaccines & COVID-19
The Sordid History of Vaccines & COVID-19
Road to Total Medical Tyranny or FREEDOM? (Part 2) Read PART 1 >> A Sordid History: Vaccines Before discussing the coronavirus vaccine, let’s quickly recap the history of vaccines and the reasons that so many of us choose NOT to inject ourselves or our children. Vaccines have long been touted as the medical “saviors” of the modern world. The eradication of diseases like smallpox and measles has largely been attributed to the “miracle” of vaccination. But is that the truth? Let’s review the facts about measles and the MMR vaccine. From 1959-1962 – just before the vaccine was introduced –
·thetruthaboutcancer.com·
The Sordid History of Vaccines & COVID-19
There is no such thing as a mandatory vaccine! - YouTube
There is no such thing as a mandatory vaccine! - YouTube
Click here to subscribe - https://www.glutenfreesociety.org/wxrn Vaccines have to be proven as safe and effective before they can be mandated or implemented. COVID-19's actual estimated mortality rate does not dictate a national emergency. You've got to look ahead at this and ask yourself "am I going to allow this?" You are going to have a choice to make. However, I think that there will be enough "volunteers" that are willing to receive the vaccine. All that being said, I don't think that any chemical injected into your body works better than your innate immune system when you take care of your body. **Coronavirus resource page: https://www.glutenfreesociety.org/viral-outbreaks ** The products, supplements, vitamins, minerals, herbs, etc mentioned in these videos and article are not intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. There currently are no vaccines, pills, potions, lotions, lozenges or other prescription or over the-counter products available to treat or cure coronavirus disease 2019 (COVID-19) The information in these videos, and article is provided for educational purposes and should not be construed as medical advice. If you are seeking medical advice in regards to COVID-19 please visit the WHO website: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen To connect with Dr. Osborne visit: On the web: https://drpeterosborne.com/ Facebook: https://www.facebook.com/DoctorPeterO... Pinterest: https://www.pinterest.com/docosborne/ Instagram: https://www.instagram.com/drosborne Twitter: https://twitter.com/glutenology *These statements have not been evaluated by the Food and Drug Administration. This video is not intended to diagnose, treat, cure or prevent any disease. It is strictly intended for educational purposes only. Additionally, this information is not intended to replace the advice of your physician. Dr. Osborne is not a medical doctor. He does not treat or diagnose disease. He offers nutritional support to people seeking an alternative from traditional medicine. Dr. Osborne is licensed with the Pastoral Medical Association.
·youtube.com·
There is no such thing as a mandatory vaccine! - YouTube
Vaccine Stampede
Vaccine Stampede
Vaccines usually are at the edge of our consciousness, but now with COVID-19 running amuck in the world, vaccines are very much in our minds. Because of the controversy, and the heavy hand the media and government play against anyone that doubts the mainstream narrative, we tend to keep quiet, keep our mouths shut instead... View Article
·drsircus.com·
Vaccine Stampede
What’s in the COVID-19 vaccines
What’s in the COVID-19 vaccines
Christiane Northrup, April 16, 2021 What's in Covid vaccine? More on Dr Northrup "Christiane Northrup, M.D., is a visionary pioneer and a leading authority in the field of women’s health and wellness, which includes the unity of mind, body,…
·bitchute.com·
What’s in the COVID-19 vaccines
Yale Study To Manipulate Americans Into Taking C0VlD Vaccine - YouTube
Yale Study To Manipulate Americans Into Taking C0VlD Vaccine - YouTube
Yale University is conducting a study to figure out how to best create effect "messaging" in order to convince Americans to take the upcoming C0VlD vaccine.  In reality, their methods are nothing short of manipulation.  We break them down in detail. Check out our NEW Free Speech Platform https://ISE.Media ---------------- Support Truth in Media by visiting our sponsors: ISE.Media https://ISE.Media Pulse Cellular: Use code "TRUTH" for 10% every plan for life. https://truthinmedia.com/phone Pure VPN: Military grade vpn protection. https://truthinmedia.com/vpn Brave Browser: Open source and built by a team of privacy focused, performance oriented pioneers of the web. https://truthinmedia.com/brave #benswann
·youtube.com·
Yale Study To Manipulate Americans Into Taking C0VlD Vaccine - YouTube
Potential Role of Acacia Senegal (Gum Arabic) as Immunomodulatory Agent among newly diagnosed COVID 19 Patients
Potential Role of Acacia Senegal (Gum Arabic) as Immunomodulatory Agent among newly diagnosed COVID 19 Patients
Objectives To investigate the potential efficacy of Acacia Senegal extract Gum Arabic (GA) supplementation as immunomodulatory and anti-inflammatory dietary intervention among newly diagnosed COVID 19 Sudanese patients. To study the effect of GA on the level of cytokines, TNFα, IL8, IL6 IL10, CRP and the viral load. Secondary outcomes will be the effect of GA oral intake on mortality rate and days of hospital admission. Trial design Quadruple blind, randomized placebo-controlled clinical trial Phase II & III. Prospective, two-arm, parallel-group, randomised (1:1 allocation ratio) superiority trial of oral GA among seropositive COVID-19 patients. Participants Inclusion criteria: COVID-19 infected (newly diagnosed) as proved by real-time PCR within 72 hours of PCR. Age 8-90 years Both genders Exclusion criteria: Intubated patients on parenteral treatment Allergy to Gum Arabic The study will be conducted in COVID Isolation Centres and Soba University Hospital Khartoum State Sudan. Intervention and comparator Experimental: Intervention Group This arm will receive 100% natural Gum Arabic provided in a powder form in 30-grams-dose once daily for four weeks Placebo Comparator: Control group: This group will be provided with pectin powder provided as one-gram-dose once daily for four weeks Both GA and placebo will be in addition to standard care treatment based on local clinical guidelines. Main outcomes Mean change from baseline score of Immune Response to end of the trial. Changes of the level of Tumor Necrosis Factor (TNFα), interleukin IL8, IL6, and IL10 from the baseline values (Four weeks from the start of randomization). Mortality rate: The percentage of deaths among COVID 19 patients received Gum Arabic compared to placebo (Four weeks from the start of randomization]). Randomisation Randomization (1:1 allocation ratio) and will be conducted using a sequence of computer-generated random numbers by an independent individual. Each participating centre will be assigned a special code generated by the computer. The randomization will be kept by the PI and a research assistant. Blinding (masking) Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Numbers to be randomised (sample size) 110 eligible patients will be randomly assigned to either GA (n=55) or placebo (n=55) groups. Trial Status Protocol Version no 2, 30th June 2020. Recruitment will start on 15th September 2020. The intended completion date is 15th January 2021. Trial registration ClinicalTrials.gov Identifier: NCT04381871 . Date of trial registration: 11 May 2020. Full protocol The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
·trialsjournal.biomedcentral.com·
Potential Role of Acacia Senegal (Gum Arabic) as Immunomodulatory Agent among newly diagnosed COVID 19 Patients
Potential Immunoregulatory and AntiviralSARS-CoV-2 Activities of Nitric Oxide - PubMed
Potential Immunoregulatory and AntiviralSARS-CoV-2 Activities of Nitric Oxide - PubMed
Nitric oxide (NO) represents a key signaling molecule in multiple regulatory pathways underlying vascular, metabolic, immune, and neurological function across animal phyla. Our brief critical discussion is focused on the multiple roles of the NO signaling pathways in the maintenance of basal physiol …
·pubmed.ncbi.nlm.nih.gov·
Potential Immunoregulatory and AntiviralSARS-CoV-2 Activities of Nitric Oxide - PubMed
2 ICON (Ivermectin in COvid Nineteen) study Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19 medRxiv
2 ICON (Ivermectin in COvid Nineteen) study Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19 medRxiv
Importance No therapy to date has been shown to improve survival for patients infected with SARS-CoV-2. Ivermectin has been shown to inhibit the replication of SARS-CoV-2 in vitro but clinical response has not been previously evaluated. Objective To determine whether Ivermectin is associated with lower mortality rate in patients hospitalized with COVID-19. Design and Setting Retrospective cohort study of consecutive patients hospitalized at four Broward Health hospitals in South Florida with confirmed SARS-CoV-2. Enrollment dates were March 15, 2020 through May 11, 2020. Follow up data for all outcomes was May 19, 2020. Participants 280 patients with confirmed SARS-CoV-2 infection (mean age 59.6 years [standard deviation 17.9], 45.4% female), of whom 173 were treated with ivermectin and 107 were usual care were reviewed. 27 identified patients were not reviewed due to multiple admissions, lack of confirmed COVID results during hospitalization, age less than 18, pregnancy, or incarceration. Exposure Patients were categorized into two treatment groups based on whether they received at least one dose of ivermectin at any time during the hospitalization. Treatment decisions were at the discretion of the treating physicians. Severe pulmonary involvement at study entry was characterized as need for either FiO2 ≥50%, or noninvasive or invasive mechanical ventilation. Main Outcomes and Measures The primary outcome was all-cause in-hospital mortality. Secondary outcomes included subgroup mortality in patients with severe pulmonary involvement and extubation rates for patients requiring invasive ventilation. Results Univariate analysis showed lower mortality in the ivermectin group (15.0% versus 25.2%, OR 0.52, 95% CI 0.29-0.96, P=.03). Mortality was also lower among 75 patients with severe pulmonary disease treated with ivermectin (38.8% vs 80.7%, OR 0.15, CI 0.05-0.47, P=.001), but there was no significant difference in successful extubation rates (36.1% vs 15.4%, OR 3.11 (0.88-11.00), p=.07). After adjustment for between-group differences and mortality risks, the mortality difference remained significant for the entire cohort (OR 0.27, CI 0.09-0.85, p=.03; HR 0.37, CI 0.19-0.71, p=.03). Conclusions and Relevance Ivermectin was associated with lower mortality during treatment of COVID-19, especially in patients who required higher inspired oxygen or ventilatory support. These findings should be further evaluated with randomized controlled trials. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial n/a ### Funding Statement No funding. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Study was approved by the Broward Health IRB All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes De-dentified data is available upon request and approval by the Broward Health IRB.
·medrxiv.org·
2 ICON (Ivermectin in COvid Nineteen) study Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19 medRxiv
3 Vitamin D & Ivermectin Better Solutions to COVID than Vaccines
3 Vitamin D & Ivermectin Better Solutions to COVID than Vaccines
People are dying, but what are they dying from? Is it an all-powerful virus that is doing hundreds of thousands of people in, or is it medical ignorance and medical malpractice? Ignorance is deadly in medicine and is usually sourced in arrogance and pharmaceutical greed and power, which is in full view with the American... View Article
·drsircus.com·
3 Vitamin D & Ivermectin Better Solutions to COVID than Vaccines
ICON (Ivermectin in COvid Nineteen) study Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID
ICON (Ivermectin in COvid Nineteen) study Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID
Importance No therapy to date has been shown to improve survival for patients infected with SARS-CoV-2. Ivermectin has been shown to inhibit the replication of SARS-CoV-2 in vitro but clinical response has not been previously evaluated. Objective To determine whether Ivermectin is associated with lower mortality rate in patients hospitalized with COVID-19. Design and Setting Retrospective cohort study of consecutive patients hospitalized at four Broward Health hospitals in South Florida with confirmed SARS-CoV-2. Enrollment dates were March 15, 2020 through May 11, 2020. Follow up data for all outcomes was May 19, 2020. Participants 280 patients with confirmed SARS-CoV-2 infection (mean age 59.6 years [standard deviation 17.9], 45.4% female), of whom 173 were treated with ivermectin and 107 were usual care were reviewed. 27 identified patients were not reviewed due to multiple admissions, lack of confirmed COVID results during hospitalization, age less than 18, pregnancy, or incarceration. Exposure Patients were categorized into two treatment groups based on whether they received at least one dose of ivermectin at any time during the hospitalization. Treatment decisions were at the discretion of the treating physicians. Severe pulmonary involvement at study entry was characterized as need for either FiO2 ≥50%, or noninvasive or invasive mechanical ventilation. Main Outcomes and Measures The primary outcome was all-cause in-hospital mortality. Secondary outcomes included subgroup mortality in patients with severe pulmonary involvement and extubation rates for patients requiring invasive ventilation. Results Univariate analysis showed lower mortality in the ivermectin group (15.0% versus 25.2%, OR 0.52, 95% CI 0.29-0.96, P=.03). Mortality was also lower among 75 patients with severe pulmonary disease treated with ivermectin (38.8% vs 80.7%, OR 0.15, CI 0.05-0.47, P=.001), but there was no significant difference in successful extubation rates (36.1% vs 15.4%, OR 3.11 (0.88-11.00), p=.07). After adjustment for between-group differences and mortality risks, the mortality difference remained significant for the entire cohort (OR 0.27, CI 0.09-0.85, p=.03; HR 0.37, CI 0.19-0.71, p=.03). Conclusions and Relevance Ivermectin was associated with lower mortality during treatment of COVID-19, especially in patients who required higher inspired oxygen or ventilatory support. These findings should be further evaluated with randomized controlled trials. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial n/a ### Funding Statement No funding. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Study was approved by the Broward Health IRB All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes De-dentified data is available upon request and approval by the Broward Health IRB.
·medrxiv.org·
ICON (Ivermectin in COvid Nineteen) study Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID
Ivermectin a systematic review from antiviral effects to COVID-19 complementary regimen The Journal of Antibiotics
Ivermectin a systematic review from antiviral effects to COVID-19 complementary regimen The Journal of Antibiotics
Ivermectin proposes many potentials effects to treat a range of diseases, with its antimicrobial, antiviral, and anti-cancer properties as a wonder drug. It is highly effective against many microorganisms including some viruses. In this comprehensive systematic review, antiviral effects of ivermectin are summarized including in vitro and in vivo studies over the past 50 years. Several studies reported antiviral effects of ivermectin on RNA viruses such as Zika, dengue, yellow fever, West Nile, Hendra, Newcastle, Venezuelan equine encephalitis, chikungunya, Semliki Forest, Sindbis, Avian influenza A, Porcine Reproductive and Respiratory Syndrome, Human immunodeficiency virus type 1, and severe acute respiratory syndrome coronavirus 2. Furthermore, there are some studies showing antiviral effects of ivermectin against DNA viruses such as Equine herpes type 1, BK polyomavirus, pseudorabies, porcine circovirus 2, and bovine herpesvirus 1. Ivermectin plays a role in several biological mechanisms, therefore it could serve as a potential candidate in the treatment of a wide range of viruses including COVID-19 as well as other types of positive-sense single-stranded RNA viruses. In vivo studies of animal models revealed a broad range of antiviral effects of ivermectin, however, clinical trials are necessary to appraise the potential efficacy of ivermectin in clinical setting.
·nature.com·
Ivermectin a systematic review from antiviral effects to COVID-19 complementary regimen The Journal of Antibiotics